EP0259085A1 — 2-Guanidino-4-arylthiazoles for treatment of peptic ulcers
Assigned to Pfizer Inc · Expires 1988-03-09 · 38y expired
What this patent protects
2-Guanidino-4-aryfthiazole compounds of the formula a pharmaceutically acceptable cationic or acid addition salt thereof wherein R 1 is hydrogen, (C 1 -C 10 )alkyl, optionally substituted phenyl or certain optionally substituted aralkyl groups; R 2 is hydrogen or (C…
USPTO Abstract
2-Guanidino-4-aryfthiazole compounds of the formula a pharmaceutically acceptable cationic or acid addition salt thereof wherein R 1 is hydrogen, (C 1 -C 10 )alkyl, optionally substituted phenyl or certain optionally substituted aralkyl groups; R 2 is hydrogen or (C 1 -C 4 )alkyl, and Ar is certain optionally substituted pyrrolyl or indolyl groups; method for their use in treatment of gastric ulcers, by inhibition of parietal cell H + /K + ATPase, and antiinflammatory conditions in combination with piroxicam, for use in mammals, and pharmaceutical compositions containing said compounds.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.